Jichuang Wang , Nan Zhang , Qi Han , Wenxian Lu , Long Wang , Dayun Yang , Min Zheng , Zhenzhen Zhang , Hekun Liu , Tae Ho Lee , Xiao Zhen Zhou , Kun Ping Lu
{"title":"对 \"Pin1抑制通过Gli1/Snail/E-cadherin通路逆转人肝癌细胞对瑞戈非尼的获得性抗性 \"的更正 [Cancer Lett. 444 (2019) 82-93].","authors":"Jichuang Wang , Nan Zhang , Qi Han , Wenxian Lu , Long Wang , Dayun Yang , Min Zheng , Zhenzhen Zhang , Hekun Liu , Tae Ho Lee , Xiao Zhen Zhou , Kun Ping Lu","doi":"10.1016/j.canlet.2024.217257","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":9506,"journal":{"name":"Cancer letters","volume":"604 ","pages":"Article 217257"},"PeriodicalIF":9.1000,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Corrigendum to “Pin1 inhibition reverses the acquired resistance of human hepatocellular carcinoma cells to Regorafenib via the Gli1/Snail/E-cadherin pathway” [Cancer Lett. 444 (2019) 82–93]\",\"authors\":\"Jichuang Wang , Nan Zhang , Qi Han , Wenxian Lu , Long Wang , Dayun Yang , Min Zheng , Zhenzhen Zhang , Hekun Liu , Tae Ho Lee , Xiao Zhen Zhou , Kun Ping Lu\",\"doi\":\"10.1016/j.canlet.2024.217257\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":9506,\"journal\":{\"name\":\"Cancer letters\",\"volume\":\"604 \",\"pages\":\"Article 217257\"},\"PeriodicalIF\":9.1000,\"publicationDate\":\"2024-09-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer letters\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0304383524006529\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer letters","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0304383524006529","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
Corrigendum to “Pin1 inhibition reverses the acquired resistance of human hepatocellular carcinoma cells to Regorafenib via the Gli1/Snail/E-cadherin pathway” [Cancer Lett. 444 (2019) 82–93]
期刊介绍:
Cancer Letters is a reputable international journal that serves as a platform for significant and original contributions in cancer research. The journal welcomes both full-length articles and Mini Reviews in the wide-ranging field of basic and translational oncology. Furthermore, it frequently presents Special Issues that shed light on current and topical areas in cancer research.
Cancer Letters is highly interested in various fundamental aspects that can cater to a diverse readership. These areas include the molecular genetics and cell biology of cancer, radiation biology, molecular pathology, hormones and cancer, viral oncology, metastasis, and chemoprevention. The journal actively focuses on experimental therapeutics, particularly the advancement of targeted therapies for personalized cancer medicine, such as metronomic chemotherapy.
By publishing groundbreaking research and promoting advancements in cancer treatments, Cancer Letters aims to actively contribute to the fight against cancer and the improvement of patient outcomes.